Synovus Financial’s Pacira BioSciences PCRX Stock Holding History

Synovus Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19	Closed	-$1K	–	1974
2020 Q1	$1K	Sell	19 -46	-71%	-$1.91K	﹤0.01%	2053
2019 Q4	$3K	Hold	65	–	–	﹤0.01%	1387
2019 Q3	$2K	Hold	65	–	–	﹤0.01%	1394
2019 Q2	$3K	Hold	65	–	–	﹤0.01%	1296
2019 Q1	$2K	Hold	65	–	–	﹤0.01%	1354
2018 Q4	$3K	Hold	65	–	–	﹤0.01%	1273
2018 Q3	$3K	Hold	65	–	–	﹤0.01%	1302
2018 Q2	$2K	Hold	65	–	–	﹤0.01%	1199
2018 Q1	$2K	Buy	+65	New	+$2.31K	﹤0.01%	1163
2017 Q2	–	Sell	-65	Closed	-$3K	–	1020
2017 Q1	$3K	Hold	65	–	–	﹤0.01%	1049
2016 Q4	$2K	Buy	+65	New	+$2.17K	﹤0.01%	1020
2015 Q2	–	Sell	-180	Closed	-$16K	–	1016
2015 Q1	$16K	Hold	180	–	–	﹤0.01%	802
2014 Q4	$16K	Buy	+180	New	+$17K	﹤0.01%	805

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Synovus Financial's PCRX Position: Q2 2020 in Review

Synovus Financial sold out of Pacira BioSciences (PCRX) in Q2 2020, closing a stake of 19 shares — an estimated $1K sold.

Synovus Financial first reported a position in PCRX in Q4 2014 and held it in 13 quarters. The position peaked at $16K in Q1 2015. 248 funds tracked by Wall St. Rank hold PCRX as of Q2 2020.

Synovus Financial reported no remaining Pacira BioSciences position as of Q2 2020 after selling out during the quarter.
Synovus Financial sold 19 Pacira BioSciences shares in Q2 2020, an estimated $1K.
Synovus Financial first reported a position in Pacira BioSciences in Q4 2014 and held it in 13 quarters.
Synovus Financial's Pacira BioSciences position peaked at $16K in Q1 2015.
248 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2020.

Based on Synovus Financial's 13F filing for Q2 2020, filed 10 Aug 2020.